

Hypertension in adults (update) Committee meeting

Date: 07/06/2018

Location: NGC Boardroom, Royal College of Physicians, 11 St Andrew's Place, London NW1 4LE

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:		
Anthony Wierzbicki (Chair)		(Present for notes 1–5)
Liz Clark		(Present for notes 1–5)
Mark Glover		(Present for notes 1–5)
Judith Magowan		(Present for notes 1–5)
Irene McGill		(Present for notes 1–5)
Lucy Pollock		(Present for notes 1–5)
Mark Shapley		(Present for notes 1–5)
Co-opted member		
Parijat De		(Present for notes 1–5)

In attendance:		
Caroline Kier	Guideline Commissioning Manager, NICE	(Present for notes 1–5)
Rebecca Boffa	Senior Research Fellow, NGC	(Present for notes 1–5)
Serena Carville	Guideline Lead, NGC	(Present for notes 1–5)
Margaret Constanti	Senior Health Economist, NGC	(Present for notes 1–5)
Meredith Faust	Project Manager, NGC	(Present for notes 1–5)
Christopher Floyd	Clinical Trainee, NGC	(Present for notes 1–5)
Audrius Stonkus	Trainee Research Fellow, NGC	(Present for notes 1–5)
Rafina Yarde	Research Fellow, NGC	(Present for notes 1–5)

Apologies:	
Elizabeth Denver	Committee member

Terry McCormack	Committee member
Richard McManus	Committee member
Allison Warren	Committee member
Bryan Williams	Committee member
Catherine Baden-Daintree	Senior Medical Editor, NICE
Beatriz Ferrer-Quiles	Information Specialist, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the eighth meeting of Hypertension in adults. The committee members and attendees introduced themselves.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included second-, third-, and fourth-line drug sequencing reviews.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was second-, third-, and fourth-line drug sequencing.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Parijat De	Co-opted committee member	Direct financial	I have received speaker fees for educational talks in diabetes from most companies but not from any pharmaceutical companies regarding hypertension		Upon appointment		No action other than the process of open declaration

The Chair and a senior member of the Developer's team noted that the interests previously declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Questions and discussion

- A. The Chair reviewed the included and excluded populations for the guideline. The committee asked questions.
- B. Rafina Yarde, Research Fellow at the NGC, presented the evidence for the review question 'What is the most clinically and cost-effective sequence for second- and third-line treatment for hypertension?' The committee discussed and asked questions about the clinical evidence and drafted recommendations.
- C. Audrius Stonkus, Trainee Research Fellow at the NGC, presented the evidence for the review question 'What is the most clinically and cost-effective sequence for fourth-line treatment for hypertension?' The committee discussed and asked questions about the clinical evidence and drafted recommendations.
- D. The committee discussed the recommendations and write-up for review question 1.1: In people with suspected hypertension, which test is most accurate in identifying whether hypertension is present, as indicated by the reference standard, ambulatory blood pressure measurement?
- E. The committee discussed the recommendations and write-up for review question 5.1: What is the clinical and cost-effectiveness of relaxation therapies for the management of primary hypertension in adults?

5. Any other business

None.

Date of next meeting: 11/07/2018

Location of next meeting: NGC Boardroom, Royal College of Physicians, 11 St Andrew's Place, London NW1 4LE